Entities

Senior Advisor to Enavate Sciences and biotechnology entrepreneur. Led Delphi Ventures’ biotechnology practice from 2001 through 2023; previously worked in healthcare finance at J.P. Morgan and conducted immunology research at Genentech.

Enavate Sciences board member and Patient Square Capital partner who leads Patient Square Insights. Previously held leadership roles at BCG, QIAGEN and McKinsey, including genomic clinical decision support and healthcare analytics. Holds a UCLA doctorate in cognitive neuroscience. Laura Furmanski is a partner and leads Patient Square Insights. She previously led healthcare consulting and analytics work at Boston Consulting Group and QIAGEN’s bioinformatics business, including genomic clinical decision software.

Enavate Sciences board member and founding partner of Patient Square Capital. A physician and healthcare investor with prior roles at KKR and Linden Capital Partners; trained at Harvard and MIT and studied neuroscience at Oxford. Neel Varshney serves as Founding Partner at Patient Square Capital. Earlier experience includes a Managing Director on KKR’s Americas Health Care Team.

Senior Advisor to Enavate Sciences and founder and managing director of Beacon Prince Partners. Previously led immunology and oncology strategy at Sanofi, ran NKT Therapeutics and Alinea Pharmaceuticals, and invested with Boston Millennia Partners. Trained in medical oncology.

Enavate Sciences board member and physician with healthcare investment experience at Patient Square Capital and HealthQuest Capital. Previously trained in internal medicine at Stanford and holds Stanford medical and business degrees. Trit Garg is a healthcare investment principal at Patient Square Capital and an Enavate Sciences director. He previously invested at HealthQuest Capital and trained in internal medicine at Stanford. He holds Stanford medical and business degrees.

Chairman of Enavate Sciences and Managing Partner of Patient Square Capital. Previously led KKR’s Americas healthcare investment team and helped establish its healthcare industry group; studied at Stanford. Jim Momtazee is Patient Square Capital’s managing partner and a healthcare investment executive. He previously helped establish KKR’s healthcare investment group and led its Americas healthcare team. He also chairs Enavate Sciences.

Vice President at Enavate Sciences focused on sourcing, diligence and investment execution. Previously led portfolio strategy and business development at Code Biotherapeutics and invested in biopharma at NEA; began his career in healthcare banking at Credit Suisse.

Vice President on Enavate Sciences’ investment team. Evaluates opportunities and supports portfolio development, drawing on prior work at Roivant and rare disease gene therapy development at Aruvant.

Principal at Enavate Sciences, executing investments and supporting portfolio operations. Previously invested with Longitude Capital and worked in healthcare investment banking at J.P. Morgan. Studied neuroscience at Penn and finance at Wharton.

Business Manager at Enavate Sciences, overseeing operational processes and strategic initiatives. Previously worked in group operations at Credit Suisse and built retail and hospitality operations; studied sociology in India.

Executive Vice President for Search and Evaluation at Enavate Sciences. A physician and investment professional with experience at OrbiMed and in healthcare investment banking at Credit Suisse and Merrill Lynch; supports investment selection and portfolio governance.

Executive Vice President for Commercialization at Enavate Sciences. Helps evaluate investments and supports portfolio strategy, partnerships and commercialization. A trained physician, he previously spent more than two decades with McKinsey’s life sciences practice. He also serves as a director of Sudo Biosciences.

Chief Executive Officer of Enavate Sciences and a member of its board. Previously led investment banking at SVB Leerink and worked in healthcare investment banking at Merrill Lynch, advising life science companies on financing and acquisitions. He also serves on the board of Graviton Bioscience. James Boylan serves as Senior Advisor at Patient Square Capital.

New York biotechnology investment and company-building platform formed by Patient Square Capital in May 2022. It invests in therapeutic and enabling technology companies and supports their clinical development, strategy and commercialization. Its neuroscience investments include CAMP4's regulatory RNA therapies, Sudo Biosciences' precision TYK2 inhibitors and Graviton's ROCK2 programs. Patient Square announced an initial $300 million capital commitment at launch; this was a commitment to the investment platform, rather than a verified cash draw or a standalone fund close.

Asahi Kasei Ventures is the corporate venture capital program of Asahi Kasei, a Japanese group active in materials, homes and healthcare. It invests in startups and supports joint development with the group’s operating businesses to create new commercial opportunities. Its portfolio spans biotechnology, medical devices, digital health, semiconductors, industrial software, construction technology, climate technology and advanced materials. The program invests across company stages through teams in the United States, Europe, China and Japan, with healthcare work including rare-disease drug developer Glycomine. Its published team includes professionals from affiliated Asahi Kasei Therapeutics/Veloxis Pharmaceuticals and Homes Ventures. The program is distinct from the parent corporation and from any individual corporate investing subsidiary or pharmaceutical business.

Sanderling Ventures is a biomedical venture capital firm that finances and helps build early-stage life-sciences companies. It combines seed and venture investment with hands-on company management, scientific and regulatory support, operational leadership and later financing. Its investments span drug development, medical technology and digital health, including rare-disease developer Glycomine. Founded in 1979, Sanderling works with entrepreneurs from company formation through clinical and commercial development and has backed more than 90 biomedical companies. Its published roster includes investment managers, venture partners, legal counsel and an emeritus managing director, alongside a memorial to late founding partner Robert G. McNeil.

Jeff Chen is an Asahi Kasei corporate venture capital managing director who joined the team in 2023 after leading product management and development at semiconductor company Crystal IS. He holds a Stony Brook electrical-engineering doctorate and an NYU Stern MBA.

Andy Schwab serves as Director at CAMP4 Therapeutics. 5AM Ventures investment leader whose biotechnology investing and board experience includes CAMP4 and multiple therapeutic and life science technology companies.

Benjamin Neale serves as Scientific Advisor at CAMP4 Therapeutics. Genetics researcher at the Broad Institute and co-director of its Stanley Center for Psychiatric Research.

Christopher Walsh serves as Scientific Advisor at CAMP4 Therapeutics. Physician-scientist studying the genetics of brain development and neurological disease.

David Bumcrot serves as Scientific Fellow at CAMP4 Therapeutics. RNA therapeutics scientist and CAMP4 scientific fellow; previously served as the company’s chief scientific officer before its October 2025 leadership transition.

Karen Adelman serves as Scientific Advisor at CAMP4 Therapeutics. Gene regulation researcher advising CAMP4 on its regulatory RNA science.

Leonard Zon serves as Scientific Advisor at CAMP4 Therapeutics. CAMP4 scientific co-founder and physician-scientist affiliated with Boston Children’s Hospital and Harvard; advises the company on genetic disease biology.

Murray Stewart serves as Director at CAMP4 Therapeutics. Physician and biotechnology director who chairs CAMP4’s research and development committee.

Rachel Meyers serves as Scientific Fellow at CAMP4 Therapeutics. RNA therapeutics scientist serving as a scientific fellow at CAMP4.

Wendy Chung serves as Scientific Advisor at CAMP4 Therapeutics. Physician-scientist and human genetics specialist advising CAMP4 on genetic disease research.

Alla Sigova serves as Senior Vice President, Platform at CAMP4 Therapeutics. Founding scientist who helped build CAMP4’s gene control mapping technology in 2016. Leads experimental and computational platform teams and previously worked on RNA therapeutics at Laronde.

Michael MacLean serves as Director at CAMP4 Therapeutics. Biotechnology finance executive appointed to CAMP4’s board in March 2026.

Steve Holtzman serves as Director at CAMP4 Therapeutics. Biotechnology company director who previously chaired CAMP4; the company announced his transition to an independent director role in September 2025.

Satya Kuchimanchi serves as Senior Vice President, Technical Operations at CAMP4 Therapeutics. Drug development and manufacturing specialist overseeing technical operations; trained in organic chemistry at Osmania University.

Caleb Moore serves as Chief Business Operations Officer at CAMP4 Therapeutics. Leads program strategy, portfolio decisions, alliance management and business operations; previously worked in corporate development at Acceleron Pharma.

Daniel Tardiff serves as Chief Scientific Officer at CAMP4 Therapeutics. Previously led rare neurological disease research at Pfizer and helped found Yumanity Therapeutics, where his work included Parkinson’s disease drug discovery.

Michelle Gates serves as Chief People Officer at CAMP4 Therapeutics. Human resources leader who previously spent sixteen years at Akamai Technologies, supporting international expansion, acquisitions and organizational development.

Yuri Maricich serves as Chief Medical Officer at CAMP4 Therapeutics. Physician and drug development executive overseeing CAMP4’s clinical development strategy. PKG Health appointed physician-scientist Yuri Maricich Chief Medical and Scientific Officer in August2023 and assigned him leadership of its Clinical Advisory Board. Its biography describes therapeutic-development work at Xdynia, Cavion, Corixa and Pear Therapeutics and education at Harvard, Washington, Notre Dame and Virginia. PKG’s July2025 directory retains his medical/scientific title; subsequent tenure after Empatica’s acquisition is unconfirmed and his separately established CAMP4 role is preserved.

Kelly Gold serves as Chief Financial Officer at CAMP4 Therapeutics. Biotechnology finance executive responsible for CAMP4’s financial strategy and operations.

CuraSen Therapeutics is a clinical-stage biotechnology company developing oral small-molecule medicines for neurodegenerative and psychiatric diseases. It targets adrenergic receptors to compensate for declining noradrenergic signalling in the brain. Its investigational pipeline includes CuraAX (CST-3056), an alpha-1A adrenoceptor agonist being studied for neurogenic orthostatic hypotension in Parkinson’s disease and related conditions, and the CuraCN and CuraXN beta-2 adrenoceptor agonist combinations for neurodegenerative disease. The company conducts drug discovery and clinical development from San Carlos, California; its medicines remain investigational.

Atlanta-based biopharmaceutical investment manager focused on emerging biotechnology companies. It manages the Trails Edge Biotechnology Master Fund and participates in negotiated public company financings, including ProMIS Neurosciences' antibody programs for neurodegenerative diseases and Immunic's multiple sclerosis drug development. Its publicly documented investments also include CAMP4 Therapeutics and ImageneBio.

Chief Financial Officer, Chief Operating Officer and Chief Compliance Officer of Trails Edge Capital Partners. The firm's SEC adviser filing identifies him as Matthew James Diaz; he signs biotechnology investment purchase agreements on behalf of the Trails Edge Biotechnology Master Fund.

Chief Investment Officer and principal of Trails Edge Capital Partners, the investment manager of the Trails Edge Biotechnology Master Fund. SEC filings identify him as Ortav Daniel Yehudai and document his authority over the manager's biotechnology investments.

CTI Life Sciences Fund is a Montreal-based life-sciences venture capital firm and biotechnology company builder. It finances therapeutic assets and platforms from company formation through clinical development, supporting scientific validation, management, financing and eventual exits. The firm invests across therapeutic areas and drug modalities; its portfolio includes neuroscience-related programs at Aeovian Pharmaceuticals and Find Therapeutics, AI-enabled drug discovery at Phenomic AI, and rare-disease substrate replacement therapies at Glycomine. CTI operates a succession of investment funds and works with academic, pharmaceutical and biotechnology partners to create companies around promising research.

Chiesi Ventures is a life-sciences venture investment firm established through a strategic collaboration between the Chiesi pharmaceutical group and Pappas Capital. It backs early-stage companies developing treatments, diagnostic tools and disease-management technologies for rare and orphan diseases. Its focus spans small molecules and biologics, advanced therapies, drug-delivery technologies and medical devices, with investment and company-development support in the United States and Europe. Its portfolio includes Glycomine, which develops therapies for rare metabolic disorders with neurological symptoms, and Minoryx Therapeutics, which develops treatments for rare central nervous system diseases. The published investment committee reflects the Chiesi and Pappas partnership, with Chiesi holding the majority.

Vice president of investor relations and communications at Immunic. Named as the company’s current investor contact on its official investor relations site and in company presentations.

Independent director of Immunic and former interim board chair. Previously led neuroscience and rare disease business strategy at Roche, with experience commercializing Ocrevus and other specialty medicines.

Independent director of Immunic and neurologist with expertise in multiple sclerosis. Previously led research and clinical programs at the Cleveland Clinic and worked at Biogen; trained at Case Western Reserve and Rochester.

Independent director of Immunic, also known as Buck Phillips. Life sciences finance and operations executive with experience at Ribometrix, G1 Therapeutics, Novavax and Micromet and earlier venture investing experience.

Independent director of Immunic and biopharmaceutical finance executive. Has held leadership roles at Sionna, ACADIA, Alexion and Maverick Capital; trained at the University of Pennsylvania and is a CFA charterholder.

Independent director of Immunic and life sciences investor and adviser. Former Curexsys chief executive and former partner at Life Sciences Partners, with earlier investment experience at DVC and Atlas Venture.

Chair of Immunic's board. Former Cubist Pharmaceuticals chief executive and Biogen commercial leader with experience launching multiple sclerosis medicines and guiding biotechnology companies. Mike Bonney is published by Kineticos Life Sciences as Strategic Advisor. Mike Bonney is a business executive with over 30 years of biotech and pharmaceutical expertise. Bonney was CEO and Director of Cubist Pharmaceuticals from 2003 until 2014. Under his leadership, Cubist grew from a struggling micro-cap to the world’s leading antibiotic company and was acquired by Merck early in 2015 for $9.5 billion. Prior to Cubist, Bonney was Vice President of Sales and Marketing at Biogen where he built the company’s commercial infrastructure for the launch of its first product. Before joining Biogen, he spent 11 years at Zeneca Pharmaceuticals in a range of commercial, operating, and strategic roles, ending his career there as National Business Director. Bonney was a regional winner and national finalist (2013) in the life science segment of Ernst & Young’s Entrepreneur of the Year. He was one of six executives nationwide named as Marketwatch’s CEO of the Year (2011) and was named Top Performing MA CEO by Boston Business Journal in 2008. Bonney is currently a director of Alnylam Pharmaceuticals and chair of Dunad Therapeutics, Gulf of Maine Research Institute, and Autolus Therapeutics. Bonney has served as a director with many companies previously including Kaleido Biosciences, Magenta Therapeutics, Bristol Myers Squibb, Sarepta Therapeutics and Syros Pharmaceuticals. Bonney spends much of his time identifying and mentoring the next generation of life science leaders. He received his undergraduate degree in economics from Bates College. Outside-company appointments in this source summarize published experience; no additional current external employer, directorship or personal investment check is inferred.

Director of Immunic and a BVF Partners investment professional. Previously worked at Monashee, Stifel and ClearView Healthcare Partners; trained in chemical engineering at Vanderbilt and holds a Notre Dame master's degree.

General counsel of Immunic. Previously held legal leadership roles at Sandoz, Merck, Biogen and Pfizer, with experience in development, regulatory matters and commercial operations.

Chief business officer of Immunic. Previously worked in business development at Akebia and corporate development at AVEO, with earlier consulting and healthcare investment banking experience.

Chief data and digital officer of Immunic, appointed in September 2026. Leads enterprise data, analytics, AI and digital strategy; previously held data leadership roles at Avidity Biosciences, Edwards Lifesciences and Medtronic.

Chief development officer of Immunic. Has led global clinical development and operations across neurological, oncology and rare disease programs; holds a master's degree in biopharmaceutical sciences from Leiden.

Chief medical officer of Immunic, appointed in April 2026. Neurologist with drug development experience at Neurvati, GRIN Therapeutics, Wave Life Sciences, Sanofi Genzyme and Biogen.

Chief financial officer of Immunic. Joined as principal accounting officer and controller in 2019 and became CFO in 2022; previously held finance leadership roles at Pernix, Alvogen and ImClone.

Co-founder and chief scientific officer of Immunic, responsible for scientific strategy, preclinical studies and biomarkers. Previously worked at 4SC on development programs and holds a biology doctorate from Ludwig Maximilians University of Munich.

Chief executive and director of Immunic, with experience commercializing multiple sclerosis medicines. Previously held commercial leadership roles at Genentech, including work on the Ocrevus launch and the tominersen development program.

President and chief operating officer of Immunic. Previously led operations at Ovid Therapeutics and held multiple sclerosis commercial leadership roles at Novartis and Biogen.

Biotechnology company developing oral small molecule treatments for neurological and autoimmune diseases. Its lead candidate, vidofludimus calcium, combines Nurr1 activation with DHODH inhibition and is being studied in Phase 3 trials for relapsing multiple sclerosis. Earlier programs include IMU-381 and IMU-856. The company also invests in enterprise data, analytics and AI capabilities to support clinical development and potential commercialization.

Glycomine is a clinical-stage biotechnology company developing replacement therapies for serious rare genetic diseases. Its platform delivers substrates, enzymes or proteins into relevant cells to bypass disrupted biochemical pathways. Its lead investigational medicine, GLM101, delivers mannose-1-phosphate to address the metabolic defect in PMM2-congenital disorder of glycosylation, a multisystem disease with neurological symptoms including ataxia. The company completed enrollment in its global randomized Phase 2b POLAR study in April 2026. Glycomine is based in San Carlos, California.

abrdn Inc. is a U.S. registered investment adviser within Aberdeen Group, operating under the Aberdeen Investments brand. It manages equity, fixed income and alternative investment portfolios and advises U.S. closed-end funds. Its healthcare team invests in public and private biotechnology, diagnostics, medical technology and healthcare companies, including neuroscience drug developers. The firm assumed the management of four established Tekla healthcare and life-sciences funds in October 2023; those funds are older vehicles. Investment professionals from affiliated Aberdeen businesses can support its clients under personnel-sharing arrangements. It is distinct from the parent group and from abrdn Investments Limited and abrdn Asia Limited.

Jason Akus is Head of Healthcare Investments at abrdn Inc., succeeding Daniel Omstead as lead of the four former Tekla healthcare funds in June2024. He joined the predecessor adviser in2001 and formerly served as Tekla senior vice president of research. He holds a Tufts BS in Mathematics and MD/MBA. His work includes investment due diligence in biotechnology, medical devices and diagnostics; the 2026 own biography and current healthcare fund page identify his current affiliation, distinct from historical Tekla employment.

Jeffrey Lu is an Aberdeen investment director in the Asia Pacific multi-asset and investment solutions team, overseeing quantitative portfolio and risk modelling. He joined the firm in 2017 after working at HKEX.

Kelly Girskis was publicly named by Arkuda Therapeutics as Board Member. Her archived2024 issuer biography identifies an abrdn investment-director role following the October2023 Tekla transition, and previous Tekla research work covering private and public biotech. Her background includes SVB Leerink and Ascentia Asset Management and neuroscience training. Arkuda affiliation is historical; continued employment or board membership after the2025 asset sale is unverified.

Loretta Tse is an investment director for the abrdn healthcare funds in the2026 own biography. She joined abrdn in2023 from Tekla, where she had been vice president since2015. Earlier experience includes biotechnology consulting, venture funds and start-ups, and a managing director role at Fred Hutchinson Cancer Research Center. She holds a UC Davis biochemistry BS and Johns Hopkins pharmacology/molecular sciences PhD.

Robert Benson is an investment director on abrdn’s healthcare team in its2026 biography, having joined in2023 from Tekla after seven years. At Tekla he served as vice president, performing fundamental and quantitative portfolio analysis and research in small/midcap biotechnology and diagnostics. Previously he held quantitative investment research roles at State Street Global Advisors and Putnam Investments. His published education includes a Berkeley MS in Financial Engineering.

Portfolio manager at Woodline Partners covering consumer businesses, including health and wellness. The firm's published profile describes earlier healthcare investing and investment banking experience and a Wharton economics degree.

Global fundamental equity investment manager based in San Francisco, with offices in New York, West Palm Beach and London. Its industry specialists cover biotechnology, medical devices, AI infrastructure, semiconductors and other sectors. Alongside public equity strategies, it participates in private company and negotiated public company financings, including companies developing treatments for neurodegenerative and mental health disorders.

Chief financial officer of Woodline Partners, identified as Christopher Michael Todd in regulatory filings. A senior finance executive of the investment management business.

Chief compliance officer of Woodline Partners, identified as Erin Sian Mullen in regulatory filings. Oversees compliance within the investment adviser.

Co-chief investment officer of Woodline Partners, identified as Karl Heinz Kroeker in regulatory filings. A senior investment leader and principal of the investment management business.

Chief operating officer of Woodline Partners, identified as Matthew Paul Hooker in regulatory filings. A senior leader responsible for the investment management business's operations.

Co-founder and co-chief investment officer of Woodline Partners, identified as Michael Clifford Rockefeller in regulatory filings. Oversees investing and firm strategy and has discussed the firm's biotechnology and pharmaceutical research approach.

Clinical advisory board member of ProMIS Neurosciences. Researcher associated with the University of Gothenburg and University College London, specializing in fluid biomarkers for neurological disorders. Henrik Zetterberg is ALZpath’s Distinguished Scientific Advisor. He researches fluid biomarkers for neurological disease and holds neurochemistry appointments at the University of Gothenburg and University College London. Henrik Zetterberg is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Professor of Neurochemistry and Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg and Clinical Chemist at Sahlgrenska University Hospital. This is a foundation governance or honorary affiliation, not an assertion of operating employment. Henrik Zetterberg is listed by Vesper Bio as Scientific Advisor. Neurochemistry and fluid-biomarker researcher affiliated with Gothenburg/UCL; current Vesper scientific-advisory capacity is source-qualified separately from existing company and foundation affiliations.

Clinical advisory board member of ProMIS Neurosciences. University of California, San Francisco researcher associated with the Alzheimer’s Disease Neuroimaging Initiative and Brain Health Registry, studying brain imaging and dementia. Michael Weiner is an ALZpath scientific adviser and UCSF professor emeritus. He leads the Alzheimer’s Disease Neuroimaging Initiative and Brain Health Registry, with long-standing research in MRI and neurodegenerative disease.

Scientific advisory board member of ProMIS Neurosciences. McGill neurologist and researcher studying brain imaging, movement disorders and Parkinson’s disease.

Scientific advisory board member of ProMIS Neurosciences. King’s College London researcher studying Down syndrome, Alzheimer’s disease, biomarkers and neuropsychiatry.

Scientific advisory board member of ProMIS Neurosciences. Physician-scientist researching protein misfolding and its relationship to psychiatric and neurological disorders.

Scientific advisory board member of ProMIS Neurosciences. University of British Columbia researcher studying Alzheimer’s disease, traumatic brain injury and fluid biomarkers.

Scientific advisory board member of ProMIS Neurosciences. McGill physician-scientist studying the genetics of neurological disease, with medical training at Ottawa and a doctorate from Harvard.

Scientific advisory board member of ProMIS Neurosciences. Researcher studying RNA splicing and antisense approaches to genetic and neurological disorders.

Scientific advisory board member of ProMIS Neurosciences. Neurologist associated with the Toronto Memory Program, specializing in dementia care and clinical trials.

Scientific advisory board member of ProMIS Neurosciences. University of California, San Diego physician-scientist studying Down syndrome and Alzheimer’s disease.

Independent director of ProMIS Neurosciences and co-founder of Oliver Wyman. Management consultant and business leader with previous experience at Booz Allen.

Chairman and co-founder of ProMIS Neurosciences. Biotechnology entrepreneur with leadership experience at Genzyme, Adheris and Dart and a background in healthcare business development.

Josh Mandel-Brehm serves as President & Chief Executive Officer at CAMP4 Therapeutics. Biotechnology executive with prior business development experience at Biogen and Genzyme and entrepreneurship experience with Polaris Partners; also serves on the ProMIS Neurosciences board.

Lead independent director of ProMIS Neurosciences. Intellectual property adviser with experience in biotechnology and pharmaceutical patent strategy, including at Genzyme and Sanofi.

Independent director of ProMIS Neurosciences. Healthcare investment professional associated with Ally Bridge public equity investing and portfolio management.

Biotechnology company developing antibodies and vaccines targeting toxic misfolded proteins in neurodegenerative diseases. Its EpiSelect platform combines protein physics, computational prediction and biology to identify disease-specific epitopes. Lead antibody PMN310 is being studied in Alzheimer's disease; earlier programs target TDP-43 in ALS and frontotemporal dementia and alpha-synuclein in Parkinson's and related disorders.

Chief financial officer of ProMIS Neurosciences and founding managing director of Danforth Advisors. Provides financial leadership to life sciences companies through advisory and executive engagements.

Chief physics officer of ProMIS Neurosciences and University of Alberta researcher. Works on computational approaches to protein structure, molecular biology and therapeutic discovery.

Chief commercial officer of ProMIS Neurosciences, appointed effective October 5, 2026. Biotechnology executive with experience in neuroscience commercialization and market preparation.

Chief development officer of ProMIS Neurosciences. Life sciences executive with experience translating research into therapeutic development programs.

Chief medical officer of ProMIS Neurosciences. Neurologist and biotechnology executive with experience in neuroscience drug development and clinical research.

ProMIS Neurosciences co-founder and chief scientific officer, board director and scientific advisory board co-chair. Physician-scientist studying misfolded proteins and neurodegenerative diseases.

President and chief executive of ProMIS Neurosciences and a member of its board. Biotechnology executive with experience leading drug development companies and advancing therapeutics toward commercialization.

Pictet Alternative Advisors is the Pictet Group’s alternative investment business, managing private equity, private debt, real estate and hedge fund strategies for institutional and private clients. Its thematic private equity teams invest through specialist venture, growth and buyout funds and direct co-investments in technology, healthcare and environmental solutions. Technology includes enterprise AI, cybersecurity, fintech and deep tech; healthcare includes therapeutics, diagnostics, digital health and medical technology. Its direct private equity team also backs founder- and family-owned European businesses. It is distinct from the broader Pictet banking and wealth management group and from Pictet Asset Management.

C2N Diagnostics develops and commercializes blood biomarker tests and laboratory services for Alzheimer’s disease and other neurodegenerative disorders. Its Precivity tests use high-resolution liquid chromatography and tandem mass spectrometry to measure proteins associated with brain amyloid pathology, helping clinicians evaluate patients with cognitive symptoms. The company also supplies biomarker measurements for clinical trials and researchers, and is developing tests for tau tangle pathology. Its laboratory in St. Louis serves clinical and research customers.

GHR Foundation is an independent philanthropic foundation supporting Alzheimer’s prevention, Catholic church networks, local Catholic education and higher education. Its Alzheimer’s program backs earlier detection and prevention through biomarker diagnostics and clinical research, including C2N Diagnostics blood tests and Washington University’s inherited Alzheimer’s prevention trials. It provides grants and program-related investments and has also participated in Atalanta Therapeutics’ neurological drug-development financing. It is a charitable foundation with its own investment staff and governance committees.

Consultant on Great Point Partners' CEO Advisory Board with healthcare services leadership experience. Previously led Autism Learning Partners and Kindred Healthcare's hospital division. Studied at San Francisco University and Golden Gate University, according to the firm's biography.

Physician and healthcare executive serving as a consultant on Great Point Partners' CEO Advisory Board. Previously held marketing, strategy and corporate development leadership at Hill-Rom, Hospira and GE Healthcare. Holds Michigan economics, biomedical engineering and medical degrees.

Industrial pharmacist, pharmaceutical engineer and consultant on Great Point Partners' CEO Advisory Board. Previously led Clinical Supplies Management's European operations and B&C Group and has experience with clinical research logistics and industry associations. Graduated from the Catholic University of Louvain.

Consultant on Great Point Partners' CEO Advisory Board with healthcare technology strategy and company leadership experience. Previously worked at Strata Decision Technology, Applied Pathways, Sg2 and Allscripts and co-founded MediRegs. Holds a Michigan economics degree.

Consultant on Great Point Partners' CEO Advisory Board with clinical supply and pharmaceutical services leadership experience. Previously led Clinical Supplies Management and held development and clinical services leadership at Catalent. Holds Ohio State finance and international business degrees.

Consultant on Great Point Partners' CEO Advisory Board with pharmaceutical manufacturing and leadership experience. Previously led Eon Labs and the Sandoz division of Novartis and chaired portfolio company boards. Holds a Ludwig Maximilian University of Munich PhD.

Consultant on Great Point Partners' CEO Advisory Board with biological, medical device and drug manufacturing experience. Previously led Bionova, MaSTherCell and Cytovance and held operations roles at Immucor and Aronex. Holds a biology degree and studied executive business administration at Texas A&M.

Consultant on Great Point Partners' CEO Advisory Board with healthcare payment and services leadership experience. Previously led business development at Medlogix and worked at Sedgwick. Holds a Hofstra public accounting degree.

Member of Great Point Partners' CEO Advisory Board with experience leading healthcare and veterinary services businesses. Previously led Advantia Health, Heart + Paw and Banfield Pet Hospital. Holds Miami University and Harvard degrees. The advisory board provides consulting support.

Great Point Partners general counsel and chief compliance officer, joining in 2019. Previously worked in legal and compliance at Irving Place Capital and as a lawyer at Davis Polk and Paul Weiss. Holds NYU law and Yeshiva accounting degrees and a CPA credential.

Great Point Partners public equity analyst, joining in 2025 after biotechnology research at TD Cowen. Holds a University of Pennsylvania undergraduate degree and Weill Cornell medical degree.

Great Point Partners assistant vice president of finance, joining in 2012 and supporting fund reporting and operations. Previously worked at SS&C GlobeOp. Holds Lehigh finance and marketing degrees and an NYU MBA.

Great Point Partners head of business development and investor relations, joining in 2026. Previously led investor relations at Rock Springs Capital and business development at QVIDTVM, with earlier roles at Stephens, William Blair and Thomas Weisel. Holds a Santa Clara political science degree.

Great Point Partners executive assistant, joining in 2021. Previously supported investment professionals at A&M Capital Opportunity and Durham Asset Management.

Great Point Partners analyst, joining in 2026 after studying economics at the University of Virginia. Previously evaluated healthcare and business services investments at Interlock Equity.

Great Point Partners investor relations and event coordinator, joining at the firm's inception in 2003. Previously supported investment technology leadership at J. H. Whitney. Graduated from York College of Pennsylvania.

Great Point Partners analyst, joining in 2025 after studying biological and agricultural sciences at Cornell. Previously researched biotechnology companies as a UBS summer analyst and worked at the USDA.

Great Point Partners executive assistant, joining in 2006 after administrative roles at Amaranth Advisors and Pequot Capital Management. Holds a Purchase College fine arts degree in voice and opera performance.

Great Point Partners chief accounting officer, joining in 2007 and managing finance and operations across its funds and management company. Previously an audit associate at PwC. Holds a Binghamton accounting degree and CPA credential.

Great Point Partners public equity analyst, joining in 2024 after biotechnology research at Guggenheim Securities. Holds a University of Rhode Island pharmacy doctorate and Indiana University MBA.

Great Point Partners chief operating officer and chief financial officer, joining in 2010. Previously led finance and operations at MayerCap and ReachCapital and worked at Ziff Brothers and Deloitte. Holds an Emory business degree and CFA, CPA and financial risk management credentials.

Great Point Partners analyst, joining in 2025. Holds a Columbia neuroscience and behavior degree, with earlier work at Brean Capital and psychiatric research at Vanderbilt.

Great Point Partners senior analyst on its public equity team, joining in 2025. Previously evaluated biotechnology therapeutics at Braidwell and conducted preclinical research at Regeneron. Holds a University of Pennsylvania cell and molecular biology PhD and completed pharmacology postdoctoral research there.

Great Point Partners associate, joining in 2024 after studying philosophy, politics and economics at the University of Pennsylvania. Previously interned at Sculptor Capital Management.

Great Point Partners associate, joining in 2023. Holds a Cornell hotel administration degree with real estate and sustainability study. Previously covered healthcare IT and software during an internship at Aldrich Capital Partners.

Great Point Partners associate, joining in 2024 after medical device outsourcing investment banking work at Piper Sandler. Holds a Macalester economics and political science degree.

Great Point Partners associate, joining in 2025 after corporate development work at Optum and advisory work at Stanwich Advisors. Holds a Williams economics degree and Dartmouth MBA.

Great Point Partners associate, joining in 2026 after healthcare investment banking at TripleTree and consulting work at ettain group and Accenture. Holds a University of Virginia public policy and leadership degree.

Great Point Partners associate, joining in 2023 after graduating from Notre Dame with a finance degree. Previously interned at private equity firm Tyree & D'Angelo Partners.

Great Point Partners senior associate, joining in 2022. Holds a Wake Forest finance degree and previously interned at WCM Investment Management.

Great Point Partners vice president, joining in 2026. Previously invested in healthcare technology and services at Brighton Park Capital and Great Hill Partners. Holds a Michigan business degree and Wharton MBA.

Great Point Partners vice president, joining in 2021 after healthcare investment banking at SVB Leerink and valuation work at PwC. Holds Lehigh degrees in finance and mechanical engineering.

Great Point Partners vice president, joining in 2022 after investing in healthcare services and technology at Council Capital and working in EY investment banking. Holds a Brigham Young University finance degree.

London-based Great Point Partners vice president for business development, joining in 2022 and focusing on European opportunities. Previously worked at Vitruvian and Partners Group, including pharmaceutical services investing. Holds an Oxford medicine degree.

RNA therapeutics researcher who developed oligonucleotide technology and RNA interference drug design at UMass Medical School.

Biotechnology finance and operations executive; Atalanta’s current board directory describes him as its former CFO / COO. Previously held these roles at Jnana Therapeutics and was CFO of Dicerna Pharmaceuticals.

UMass Medical School physician-scientist and RNA therapeutics researcher with a long-standing focus on Huntington’s disease.

Healthcare venture investor and F-Prime Capital president and managing partner with previous biotechnology management and research experience. Serves as Board Member at Paradigm Health, according to its current team directory.

Physician and biotechnology entrepreneur who co-founded Comanche Biopharma and The Medicines Company. Distinct from the Blitzscaling Ventures investor Scott Johnson.

Atalanta Therapeutics develops RNA interference medicines for diseases of the central nervous system. Its divalent small interfering RNA (di-siRNA) platform is designed to durably silence disease-associated genes across the brain and spinal cord, including deep brain regions. Its current published pipeline includes programs targeting HTT and MSH3 for Huntington’s disease, NAV1.7 for pain, and undisclosed CNS targets. These are investigational programs; its website places ATL-101 in IND-enabling development. The company also develops partnered programs with Genentech.

Biotechnology business development executive with gene therapy partnering experience at Spark Therapeutics and Novartis.

RNA interference and oligonucleotide research leader; previously Dicerna chief scientific officer and head of its research unit at Novo Nordisk.

Great Point Partners principal, joining in 2016 after investing at General Atlantic and healthcare investment banking at Goldman Sachs. Holds a Dartmouth economics degree and Wharton MBA, with experience in healthcare services and pharmaceutical infrastructure investments.

Research leader with experience in neurological disease and gene editing, including scientific leadership at Affinia Therapeutics, Editas Medicine and Bristol Myers Squibb.

London-based Great Point Partners principal, joining in 2022 after European middle market private equity work at RoundShield and Waterland. Holds economics degrees from Trinity College Dublin and the London School of Economics.

Drug development executive with regulatory approval experience across infectious disease, dermatology and central nervous system therapies.

Biotechnology executive who co-founded and led Jnana Therapeutics through clinical proof of concept and its acquisition by Otsuka.

Physician-scientist specializing in movement disorders, neurogenetics and translational gene therapies; previously led gene therapy research at Spark Therapeutics.

Great Point Partners senior vice president and head of business development, joining in 2023. Previously led business development at Windham Venture Partners and corporate development at Science Exchange, and co-founded FourSight Capital Partners. Holds a West Virginia University engineering degree.

Great Point Partners principal, joining in 2015 and working on biopharmaceutical services and healthcare technology investments. Holds Notre Dame accounting and finance degrees, with earlier internships in investment banking and financial due diligence.

Great Point Partners principal, joining in 2016 after healthcare investment banking work at Stifel. Has experience with healthcare services and biotechnology manufacturing investments. Holds an Emory business degree specializing in finance and marketing.

Great Point Partners managing director, joining in 2007 after healthcare investment banking work at Cowen. Has experience with healthcare services, clinical supply and pharmaceutical services investments. Holds a Columbia economics degree.

Healthcare investment firm based in Greenwich, Connecticut, with a London office. It manages private equity funds supporting growing healthcare services, biopharmaceutical infrastructure and medical device businesses, alongside its BioMedical Value Fund strategy investing in public biotechnology and life sciences companies. Its investments include neurological gene therapy and neurophysiological monitoring, supported by investment professionals with medical and scientific training.

Founder and managing partner of Great Point Partners, established in 2003, and co-portfolio manager of its BioMedical Value Fund strategy. Previously a general partner leading healthcare investments at J. H. Whitney. Has experience investing in biotechnology, medical services and neurophysiological monitoring. Holds Boston University undergraduate and medical degrees and a Harvard MBA.

Great Point Partners managing director and co-portfolio manager of its BioMedical Value Fund strategy. Joined in 2015 following healthcare investment banking work at Guggenheim Securities. Holds a Cambridge pharmacology master's degree and Princeton molecular biology degree.

Neurogene board director and physician-scientist with experience in clinical drug development. Neurogene's current biography identifies her AbCellera chief medical officer appointment in September 2025, following earlier medical leadership at Metagenomi, Maze, Prothena and BioMarin. Holds UCSF medical, Berkeley bioengineering PhD and Dartmouth engineering degrees.

Neurogene board director and independent consultant for biopharmaceutical companies. Previously a Samsara BioCapital partner from October 2017 through April 2025, with earlier investing roles at Sofinnova and Novo and research at Roche focused on psychiatric and neurodegenerative disease targets. Holds Wake Forest pharmacology, Kellogg MBA and Connecticut College degrees.

Neurogene senior vice president and general counsel. Previously interim chief executive officer and general counsel of Neoleukin Therapeutics, leading its December 2023 merger with Neurogene. Earlier served as deputy general counsel at HomeStreet and as a partner at Davis Wright Tremaine.

Neurogene board director with biotechnology commercial and operations experience. Neurogene's current biography identifies his Scholar Rock chief operating officer appointment in April 2025, following earlier argenx and Alexion leadership. Holds a Florida State marketing degree.

Neurogene senior vice president of technical operations, joining in 2018 and leading development of its gene therapy process, analytical and manufacturing capabilities. Previously headed Lonza's Houston manufacturing facility and held gene therapy quality roles at Introgen and Vivante GMP Solutions. Holds a Texas A&M biomedical science degree.

Neurogene board director with gene therapy manufacturing and quality expertise. Previously led global manufacturing and technical operations at BioMarin and held quality roles at Genentech. Neurogene's current biography also identifies him as a Samsara BioCapital venture partner. Holds CUNY biochemistry degrees and a Regis MBA. Robert Baffi is listed by Samsara BioCapital as Venture Partner. His manufacturing and technical-operations experience includes two decades at BioMarin and earlier quality work at Genentech. He supports biotechnology product development and manufacturing readiness.

Neurogene senior vice president for regulatory affairs, quality assurance and quality control. A pediatric gastroenterologist and rare disease drug development specialist, previously leading regulatory affairs at Amicus and serving as an FDA division deputy director. Holds Columbia and Mount Sinai degrees.

Neurogene chief commercial officer with experience building commercial organizations for rare disease therapies. Previously senior vice president and general manager for North America at Avidity Biosciences and chief commercial officer at Marinus Pharmaceuticals. Also held leadership roles at Alexion, Pacira and Sanofi Biosurgery. Studied cell and molecular biology and genetics at the University of Maryland.

Neurogene chief medical officer with experience in gene therapy, rare disease and central nervous system clinical development. Previously chief medical officer at Homology Medicines and held clinical development roles at Cerevel, Avanir and Teva. Holds Harvard undergraduate and medical degrees and completed internal medicine training at Massachusetts General Hospital.